Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Walt Disney Co (DIS) vs Heron Therapeutics Inc (HRTX) Price & Performance

Walt Disney CoTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Walt Disney Co vs Heron Therapeutics Inc — how do they compare? Walt Disney Co trades at $97.31 (market cap $166.48B), while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). The key difference: Walt Disney Co is far larger — about 2017.5× Heron Therapeutics Inc's market cap, and Walt Disney Co pays a 1.56% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

DISHRTX
Market Cap
$166.48B$82.52M
Volume
7,546,013
Sector
MediaHealth
52-Week High
$122.94$2.04
52-Week Low
$92.40$0.39
Enterprise Value
$208.16B$180.42M
Dividend Yield
1.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Walt Disney Co

Disney (DIS) trades at $96.01, up 0.4% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats. Revenue grew to $94.43B in 2025 with net income surging to $12.40B. The stock shows a P/E of 15.34 and P/S of 1.77, trading below the consensus price target of $125.60. Recent news highlights advertising opportunities from major events like the Super Bowl, though box office performance for new Star Wars film raises concerns.

Outlook remains positive with analyst consensus at Buy (61.9%) and a 31% upside to target, driven by earnings momentum and theme park investments. Risks include regulatory disputes with the FCC, streaming competition, and film profitability. Cash flow trends show operational strength but negative net flows from high investing activity.

Heron Therapeutics Inc

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Walt Disney Co

The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.

Read more on DIS

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX